RenovoRx, Inc. (RNXT)

Market Cap	43.89M
Revenue (ttm)	240,000
Net Income (ttm)	-10.16M
Shares Out	36.57M
EPS (ttm)	-0.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61,771
Open	1.220
Previous Close	1.220
Day's Range	1.200 - 1.250
52-Week Range	0.750 - 1.690
Beta	1.27
Analysts	Strong Buy
Price Target	7.25 (+504.17%)
Earnings Date	Aug 14, 2025

About RNXT

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 26, 2021
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: RNXT
• Website: https://renovorx.com

Analyst Summary

According to 2 analysts, the average rating for RNXT stock is "Strong Buy." The 12-month stock price target is $7.25, which is an increase of 504.17% from the latest price.

Price Target

$7.25

(504.17% upside)

Analyst Consensus: Strong Buy